GEn1E Lifesciences
YC S19San Francisco, US · Founded 2018 · Delaware corporation · 18 employees on LinkedIn · 5 known investors
Find your way into GEn1E Lifesciences
592 people in our graph share verified history with the GEn1E Lifesciences team — schools, employers, funds. One of them is your warm intro.
Paul Kwanunlockedknows Ritu Lal · together at Stanford University (overlapped)
.jpeg)
×10knows the team · via Stanford University
knows the team · via GEn1E Lifesciences
Gen1e builds healthcare solutions supported by a network of physicians across hospitals and medical centers.
Also known as Inc.
AI & Machine LearningBiotechHealthtechMedical DevicesArtificial IntelligenceHealthcareDrug discoveryUnited States of AmericaAmerica / CanadaPartly Remote
Founders & leadership· Y Combinator alumni (S19)
GEn1E Lifesciences was founded in 2018 by Ritu Lal.
RL
Ritu LalinFounderRitu Lal holds a doctorate in pharmaceutical sciences and pharmacology from the University of Maryland and a master's degree in management from Stanford University. As CEO and co-founder of GEn1E Lifesciences, a clinical-stage biotech company, she brings over 20 years of experience in drug development, including leadership roles in preclinical and clinical programs across neurology, inflammation, virology, pain, and oncology, with multiple FDA approvals to her name.
SB
Soujanya BhumkarExecutive
Board
NK
Noor KamruddinBoard director
FN
Francois NaderBoard director
AL
Alan LevyBoard director
Investors · 5
.png)
Reported raises · per SEC filings
Form D private placements$22.5M disclosed across 2 rounds · 2022–2025
▶$5.5MraisedDec 2025 · 44 investors · BiotechnologyRule 506(b)
▶$5.5MraisedDec 2025 · 44 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ritu LalExecutive Officer, Director
- Francois NaderDirector
- Alan LevyDirector
- Noor KamruddinDirector
- Soujanya BhumkarExecutive Officer, Director
- Offering amount
- $11.9M
- Amount sold
- $5.5M
- First sale
- Oct 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$17MraisedDec 2022 · 89 investors · OtherRule 506(b)
▶$17MraisedDec 2022 · 89 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Dr. Alan LevyDirector
- Soujanya BhumkarDirector
- Noor KamruddinDirector
- Ritu LalExecutive Officer, Director
- Offering amount
- $18.2M
- Amount sold
- $17M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 6
by search overlapThumbnail for Seragon Pharmaceuticals19 shared keywordsGenentech is a biotechnology company that develops and manufactures breakthrough medicines in the United States, backed by a $50 billion commitment to U.S. manufacturing and scientific innovation.
Origene10 shared keywordsOriGene develops and supplies genomic and proteomic research tools, including proteins and antibodies built on its proprietary cDNA clone collections, for life science researchers. The company offers a broad catalog of research products used in scientific discovery and diagnostics development.
Generate Biomedicines9 shared keywordsGenerate:Biomedicines develops protein-based therapeutics using artificial intelligence and machine learning in a field it calls Generative Biology, combining computational protein design with biological engineering. The company creates new drugs on demand across diverse biologic modalities for immunology, oncology, infectious disease, and vaccines.
Regeneron NASDAQ: REGN www.regeneron.com9 shared keywordsRegeneron is a biotechnology company that develops medicines ranging from biologics to genetic medicines to treat serious diseases across areas such as metabolic disease, ophthalmology, and rare disease. The company focuses on research and development driven by human biology, with a clinical trial pipeline addressing conditions like generalized myasthenia gravis.
Genialis8 shared keywordsGenialis is a precision oncology company that applies data analysis to help drug developers understand mechanisms of action, resistance, and patient stratification for cancer therapies. It supports pharmaceutical partners in advancing molecules through clinical trials toward becoming effective medicines.
Elegen7 shared keywordsElegant Bio develops DNA synthesis technology and services, offering ENFINIA™ DNA synthesis at scale for biotech and research applications.
Companies competing with GEn1E Lifesciences for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Nykaa Stock And 2 Fast Growth Picks With High Insider Ownership - Simply Wall St Newssimplywall.st · Jul 2026Frequently asked questions
- What does GEn1E Lifesciences do?
- Gen1e builds healthcare solutions supported by a network of physicians across hospitals and medical centers.
- Who founded GEn1E Lifesciences?
- GEn1E Lifesciences was founded by Ritu Lal in 2018.
- Who are GEn1E Lifesciences's investors?
- GEn1E Lifesciences's investors include Clear Ventures, Y Combinator, Khosla Ventures, Harmonix Fund, Inflect Health.
- How much funding has GEn1E Lifesciences raised?
- GEn1E Lifesciences has disclosed $22.5M raised across 2 rounds.
- Where is GEn1E Lifesciences headquartered?
- GEn1E Lifesciences is headquartered in San Francisco, US.